Codexis (CDXS) reported a robust first quarter for 2026, with total revenue reaching $15.2 million, a significant increase from $7.5 million a year earlier, primarily due to the full recognition of revenue from its agreement with Merck. The company’s gross margin improved to 71%, up from 55%, reflecting a favorable product mix and a strategic shift away from lower-margin sales. Notably, the net loss narrowed to $8.7 million compared to $20.7 million in the same quarter last year, showcasing improved operational efficiency.
This financial performance highlights Codexis’s strategic focus on its ECO Synthesis platform, which is positioned to meet the growing demand for scalable oligonucleotide manufacturing solutions. The company anticipates annual revenue between $72 million and $76 million for 2026, with expectations for stronger performance in the latter half of the year. The ongoing development of its GMP facility in California further underscores its commitment to enhancing production capabilities.
Investors should note Codexis’s strong sales pipeline, with over 50 opportunities in the works, indicating a healthy demand for its innovative enzymatic production solutions. As the company continues to advance its technology and regulatory engagements, it is well-positioned to capitalize on the expanding market for RNA medicines.
Source: fool.com